U.S. Missile Stockpiles Decrease, FDA Considers mRNA Flu Vaccine

Why it matters locally: While the impact of decreased missile stockpiles is national, Virginia's significant defense industry, including major military installations and defense contractors, could be indirectly affected by prolonged periods of re-stocking and potential shifts in defense spending. The FDA's consideration of an mRNA flu vaccine is a national public health matter, but its approval would affect vaccine availability and public health strategies statewide, impacting organizations such as the Virginia Department of Health.

---

The U.S. Army's missile stockpiles have decreased, and officials estimate replenishment could require several years. This reduction in inventory comes as the Food and Drug Administration (FDA) considers approving a new flu vaccine that incorporates messenger RNA (mRNA) technology. Defense officials have indicated that current U.S. Army missile reserves have reached levels that necessitate a prolonged period for restoration. They project that rebuilding these stockpiles to previous capacities will take multiple years. Separately, the FDA is evaluating a flu vaccine developed with mRNA technology. This assessment will determine whether the vaccine meets regulatory standards for public use. The outcome of the FDA's review will dictate its availability.